Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA

A. Heiser, M. A. Maurice, D. R. Yancey, N. Z. Wu, P. Dahm, S. K. Pruitt, D. Boczkowski, S. K. Nair, M. S. Ballo, Eli Gilboa, J. Vieweg

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Polyvalent cancer vaccines targeting the entire antigenic spectrum on tumor cells may represent a superior therapeutic strategy for cancer patients than vaccines solely directed against single Ags. In this study, we show that autologous dendritic cells (DC) transfected with RNA amplified from microdissected tumor cells are capable of stimulating CTL against a broad set of unidentified and critical prostate-specific Ags. Although the polyclonal CTL responses generated with amplified tumor RNA-transfected DC encompassed as a subcomponent a response against prostate-specific Ag (PSA) as well as against telomerase reverse transcriptase, the tumor-specific CTL were consistently more effective than PSA or telomerase reverse transcriptase CTL to lyse tumor targets, suggesting the superiority of the polyclonal response. Although tumor RNA-transfected DC stimulated CTL, which recognized not only tumor but also self-Ags expressed by benign prostate tissue, these cross-reactive CTL were exclusively specific for the PSA, indicating an immunodominant role of PSA in the prostate cancer-specific immune response. Our data suggest that tumor RNA-transfected DC may represent a broadly applicable, potentially clinically effective vaccine strategy for prostate cancer patients, which is not limited by tumor tissue availability for Ag preparation and may minimize the risk of clonal tumor escape.

Original languageEnglish
Pages (from-to)2953-2960
Number of pages8
JournalJournal of Immunology
Volume166
Issue number5
StatePublished - Mar 1 2001
Externally publishedYes

Fingerprint

Dendritic Cells
Prostatic Neoplasms
RNA
Prostate
Neoplasms
Cancer Vaccines
Telomerase
Tumor Escape
Vaccines

ASJC Scopus subject areas

  • Immunology

Cite this

Heiser, A., Maurice, M. A., Yancey, D. R., Wu, N. Z., Dahm, P., Pruitt, S. K., ... Vieweg, J. (2001). Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. Journal of Immunology, 166(5), 2953-2960.

Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. / Heiser, A.; Maurice, M. A.; Yancey, D. R.; Wu, N. Z.; Dahm, P.; Pruitt, S. K.; Boczkowski, D.; Nair, S. K.; Ballo, M. S.; Gilboa, Eli; Vieweg, J.

In: Journal of Immunology, Vol. 166, No. 5, 01.03.2001, p. 2953-2960.

Research output: Contribution to journalArticle

Heiser, A, Maurice, MA, Yancey, DR, Wu, NZ, Dahm, P, Pruitt, SK, Boczkowski, D, Nair, SK, Ballo, MS, Gilboa, E & Vieweg, J 2001, 'Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA', Journal of Immunology, vol. 166, no. 5, pp. 2953-2960.
Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. Journal of Immunology. 2001 Mar 1;166(5):2953-2960.
Heiser, A. ; Maurice, M. A. ; Yancey, D. R. ; Wu, N. Z. ; Dahm, P. ; Pruitt, S. K. ; Boczkowski, D. ; Nair, S. K. ; Ballo, M. S. ; Gilboa, Eli ; Vieweg, J. / Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. In: Journal of Immunology. 2001 ; Vol. 166, No. 5. pp. 2953-2960.
@article{566bf7433e2b4407ace916029c757969,
title = "Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA",
abstract = "Polyvalent cancer vaccines targeting the entire antigenic spectrum on tumor cells may represent a superior therapeutic strategy for cancer patients than vaccines solely directed against single Ags. In this study, we show that autologous dendritic cells (DC) transfected with RNA amplified from microdissected tumor cells are capable of stimulating CTL against a broad set of unidentified and critical prostate-specific Ags. Although the polyclonal CTL responses generated with amplified tumor RNA-transfected DC encompassed as a subcomponent a response against prostate-specific Ag (PSA) as well as against telomerase reverse transcriptase, the tumor-specific CTL were consistently more effective than PSA or telomerase reverse transcriptase CTL to lyse tumor targets, suggesting the superiority of the polyclonal response. Although tumor RNA-transfected DC stimulated CTL, which recognized not only tumor but also self-Ags expressed by benign prostate tissue, these cross-reactive CTL were exclusively specific for the PSA, indicating an immunodominant role of PSA in the prostate cancer-specific immune response. Our data suggest that tumor RNA-transfected DC may represent a broadly applicable, potentially clinically effective vaccine strategy for prostate cancer patients, which is not limited by tumor tissue availability for Ag preparation and may minimize the risk of clonal tumor escape.",
author = "A. Heiser and Maurice, {M. A.} and Yancey, {D. R.} and Wu, {N. Z.} and P. Dahm and Pruitt, {S. K.} and D. Boczkowski and Nair, {S. K.} and Ballo, {M. S.} and Eli Gilboa and J. Vieweg",
year = "2001",
month = "3",
day = "1",
language = "English",
volume = "166",
pages = "2953--2960",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA

AU - Heiser, A.

AU - Maurice, M. A.

AU - Yancey, D. R.

AU - Wu, N. Z.

AU - Dahm, P.

AU - Pruitt, S. K.

AU - Boczkowski, D.

AU - Nair, S. K.

AU - Ballo, M. S.

AU - Gilboa, Eli

AU - Vieweg, J.

PY - 2001/3/1

Y1 - 2001/3/1

N2 - Polyvalent cancer vaccines targeting the entire antigenic spectrum on tumor cells may represent a superior therapeutic strategy for cancer patients than vaccines solely directed against single Ags. In this study, we show that autologous dendritic cells (DC) transfected with RNA amplified from microdissected tumor cells are capable of stimulating CTL against a broad set of unidentified and critical prostate-specific Ags. Although the polyclonal CTL responses generated with amplified tumor RNA-transfected DC encompassed as a subcomponent a response against prostate-specific Ag (PSA) as well as against telomerase reverse transcriptase, the tumor-specific CTL were consistently more effective than PSA or telomerase reverse transcriptase CTL to lyse tumor targets, suggesting the superiority of the polyclonal response. Although tumor RNA-transfected DC stimulated CTL, which recognized not only tumor but also self-Ags expressed by benign prostate tissue, these cross-reactive CTL were exclusively specific for the PSA, indicating an immunodominant role of PSA in the prostate cancer-specific immune response. Our data suggest that tumor RNA-transfected DC may represent a broadly applicable, potentially clinically effective vaccine strategy for prostate cancer patients, which is not limited by tumor tissue availability for Ag preparation and may minimize the risk of clonal tumor escape.

AB - Polyvalent cancer vaccines targeting the entire antigenic spectrum on tumor cells may represent a superior therapeutic strategy for cancer patients than vaccines solely directed against single Ags. In this study, we show that autologous dendritic cells (DC) transfected with RNA amplified from microdissected tumor cells are capable of stimulating CTL against a broad set of unidentified and critical prostate-specific Ags. Although the polyclonal CTL responses generated with amplified tumor RNA-transfected DC encompassed as a subcomponent a response against prostate-specific Ag (PSA) as well as against telomerase reverse transcriptase, the tumor-specific CTL were consistently more effective than PSA or telomerase reverse transcriptase CTL to lyse tumor targets, suggesting the superiority of the polyclonal response. Although tumor RNA-transfected DC stimulated CTL, which recognized not only tumor but also self-Ags expressed by benign prostate tissue, these cross-reactive CTL were exclusively specific for the PSA, indicating an immunodominant role of PSA in the prostate cancer-specific immune response. Our data suggest that tumor RNA-transfected DC may represent a broadly applicable, potentially clinically effective vaccine strategy for prostate cancer patients, which is not limited by tumor tissue availability for Ag preparation and may minimize the risk of clonal tumor escape.

UR - http://www.scopus.com/inward/record.url?scp=0035284901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035284901&partnerID=8YFLogxK

M3 - Article

C2 - 11207244

AN - SCOPUS:0035284901

VL - 166

SP - 2953

EP - 2960

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -